1 Ridiculously Cheap High-Yield Stock Worth Watching
This beaten-down master limited partnership has big-time upside potential if it can turn things around.
Editors' Picks
This Is the One Thing Netflix Should Do Better
The digital video expert simply doesn't listen to shareholder proposals. Ever.
Neiman Marcus May Be Doomed
The luxury retailer's sales and profitability are falling once again -- and it's set to face tougher competition in one key market starting this year.
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
Recent articles
Why Lululemon Looks So Much Better Than Most of Its Peers
Is yoga wear fashion or athletic gear? Maybe it doesn’t matter.
2 Reasons It May Be Time to Drop Amazon Prime
The longtime standard bearer of shipping now has some major rivals.
3 Things That Might Happen When You Live Paycheck to Paycheck
Hint: None of them are positive.
U.S. Oil Demand Was Scorching Hot Last Year -- but Gas-Guzzling SUVs Aren’t to Blame
America consumed 2.5% more crude in 2018 than in 2017, and you might be surprised where that extra oil wound up.
On Social Security? Expect a Smaller Raise in 2020
Cost-of-living increases next year aren't likely to match the 2.8% boost recipients got for 2019.
Is It Finally Safe to Buy Turtle Beach Stock?
Insiders are scooping up shares, but the company still faces formidable headwinds.
This Is the One Thing Netflix Should Do Better
The digital video expert simply doesn't listen to shareholder proposals. Ever.
Neiman Marcus May Be Doomed
The luxury retailer's sales and profitability are falling once again -- and it's set to face tougher competition in one key market starting this year.
1 Ridiculously Cheap High-Yield Stock Worth Watching
This beaten-down master limited partnership has big-time upside potential if it can turn things around.
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
The Best Cannabis Stock to Buy in June
This industry leader can help you earn a marijuana-fueled fortune.
Investors Are Selling Arista: Here's Why They're Wrong
The company that builds custom systems for the titans of the internet knows more than almost anyone what's needed to grow and scale in a cloud-first world.
4 Hard-to-Believe Driverless Car Facts
This market is bigger and has broader implications for our lives than you might think.
Where Will ExxonMobil Be in 5 Years?
The oil giant has a clearly defined five-year strategy.
Uber 1, Amazon.com 0
Amazon Restaurants' decision to bow out of its niche opens the door for Uber Eats, Grubhub, and others to cash in on the opportunity.
Winnebago Earnings: What to Watch
The RV giant should clear up some big questions for investors.
Is Chevron a Buy?
U.S. oil and gas giant Chevron just lost a big acquisition fight. Is it worth owning today without that deal?
401(k) vs. IRA: Which One Is Right for You?
The differences between them may seem slight, but you could potentially save money by choosing one type of account over the other.
Mattel Just Turned Down Another Buyout Offer; Now Things Could Get Ugly
The besieged toymaker turned down yet another potential merger opportunity, which could lead to a hostile takeover.
4 Social Security Myths That Need to Die
It's time to separate the truth from the lies.